Latest Enbrel Stories

Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab) and Cimzia(R) (certolizumab pegol)). AMGEN AND WYETH STATEMENT: The FDA has reviewed reports of histoplasmosis and other...

The Food and Drug Administration warned yesterday that a handful of medications commonly prescribed to treat rheumatoid arthritis and other serious illnesses can raise the risk of fatal fungal infections.The drugs are called Enbrel, Remicade, Humira and Cimzia. They treat arthritis by suppressing the immune system to keep it from attacking the body. The treatment provides relief from swollen and painful joints, but it's "a double-edged sword," said the FDA's Dr. Jeffrey Siegel....

By Carol M. Ostrom BOTHELL, Wash. - They are the sturdy, docile workhorses of the biotech revolution: Chinese hamster ovary cells, microscopic living factories that churn out proteins that eventually become drugs such as Enbrel, Amgen's blockbuster treatment for rheumatoid arthritis. These cells start their journey in small flasks, swirling in a nutrient broth that looks like orange Kool-Aid. For weeks, the genetically modified "CHO" cells will be gently encouraged to reproduce - and...

Doctors say a small study treating Alzheimer's patients with a popular rheumatoid arthritis drug has shown promising results, but some worry that these early finding could raise premature hopes in patients and their families.The study involved 12 patients who had greatly improved language recall shortly after treatment with Enbrel, or etanercept, an anti-inflammatory drug co-marketed by Amgen and Wyeth.Dr. Edward Tobinick, director of the Institute for Neurological Research, a private medical...

Data Demonstrated Benefits of Early Treatment in Patients with Moderate-to-Severe Rheumatoid Arthritis (RA) Amgen, Thousand Oaks Sonia Fiorenza, 805-447-1604 (media) John Shutter, 805-447-1060 (investors) or Wyeth, Collegeville Danielle Halstrom, 484-865-2020 (media) Justin Victoria, 973-660-5340 (investors) Logo: http://www.enbrel.com Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE) and Amgen (NASDAQ:AMGN) today announced the publication of data from the COMET (COmbination of...

Wyeth has reported that the European Commission has authorized a new 50mg Enbrel once weekly dosage regimen as an alternative to the currently approved 25mg Enbrel twice weekly regimen for the treatment of patients with moderate-to-severe plaque psoriasis. Based on the outcome of the extensive European 318 study in adult patients with moderate-to-severe plaque psoriasis, the European Commission issued the marketing authorization for the EU for a once weekly 50mg Enbrel dosing. The 318 study...

Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today issued the following statement on the outcome of today's meeting of the U.S. Food and Drug Administration's (FDA) Dermatologic and Ophthalmologic Drug Advisory Committee (DODAC) regarding the expanded use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis. AMGEN AND WYETH STATEMENT: The Committee recommended, with an 8-5 vote, to approve ENBREL for the...

CEL-SCI has announced the discovery of a novel peptide for the treatment of rheumatoid arthritis. This peptide, called CEL-2000, was tested in a well-established animal model of rheumatoid arthritis and was compared to Enbrel, an FDA-approved treatment for people with rheumatoid arthritis. The tests showed that CEL-2000 is equivalent or possibly superior to Enbrel in slowing disease progression and lessening symptoms in mice. In addition, the vaccine has the potential to require fewer and...

Amgen (NASDAQ:AMGN) announced that the supplemental Biologics License Application (sBLA) for ENBREL for the treatment of pediatric patients with chronic moderate to severe plaque psoriasis who have tried another therapy will be discussed today at a meeting of the DODAC. Moderate to severe plaque psoriasis is a serious, chronic inflammatory disease that can have both physical and psychosocial impact. According to a study published in the British Journal of Dermatology, chronic psoriasis can...

VIENNA, Va., June 17 /PRNewswire-FirstCall/ -- CEL-SCI Corporation today announced the discovery of a novel peptide for the treatment of rheumatoid arthritis. This peptide, called CEL-2000, was tested in a well established animal model of rheumatoid arthritis and was compared to Enbrel(R), a leading treatment for people with rheumatoid arthritis. The tests showed that CEL-2000 is equivalent or possibly superior to Enbrel in slowing disease progression and lessening symptoms in mice. In...